Despite the fact that Merck’s Zostavax shingles vaccine provides seniors with high rates of protection from the herpes zoster virus, use of the vaccine remains low, according to a new FDA study.
Nearly one in three people in the United States will develop shingles during their lifetime, with seniors being at elevated risk. The study found that the live attenuated herpes zoster vaccine (HZV) was particularly effective at providing protection against severe cases of shingles requiring